Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure

Ionis earns $5 million license fee from Dynacure CARLSBAD, Calif. and STRASBOURG, France, Nov. 9, 2017 -- (Healthcare Sales & Marketing Network) -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Dynacure announced today that Dynacure has licensed IONIS... Biopharmaceuticals, Licensing Ionis Pharmaceuticals, Dynacure, centronuclear myopathy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news